Related Experiment Video
Updated: May 6, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Approaching the increasing complexity of non-small cell lung cancer taxonomy
Marcello Maugeri-Sacca, Monica Bartucci, Alfredo Pagliuca
1"Regina Elena" National Cancer Institute, via E. Chianesi, n. 53, 00144, Rome, Italy. maugeri.marcello@gmail.com.
Abstract:
The advent of molecular targeted agents is changing the treatment of solid tumors. In non-small-cell lung cancer, compounds directed against oncogenic proteins offer novel therapeutic opportunities for a fraction of patients whose tumors harbor specific genetic defects. With the increased level of resolution achieved by high-throughput technologies, the taxonomy of lung cancer is rapidly changing. For instance, by cataloguing genetic abnormalities in squamous cell lung cancer the Cancer Genome Atlas Network revealed the existence of multiple molecular entities, each one characterized by specific molecular abnormalities, and by a different spectrum of activated/ inactivated molecular networks. Although this increased complexity could be perceived as a further drawback in effective anticancer therapy, on the other hand the combined interrogation of genomic and proteomic data is expected to provide the whole molecular map of each tumor, and to determine the information flow in the explored biological system. In particular, novel genetic and proteomic approaches are offering the opportunity for matching specific genetic defects and aberrant protein-protein interactions with active pathway-targeted inhibitors. Moreover, the isolation and characterization of a cellular pool endowed with stem-like traits, and able to recapitulate the parental disease in animals, is enabling investigators to recreate the individual patient tumor in the laboratory. In this article, we discuss how novel technologies and cellular and animal models, applied to lung cancer research, hold the potential to foster a new wave of biomarker-driven clinical trials.
Insights
Molecular targeted agents are revolutionizing solid tumor treatment, especially in non-small-cell lung cancer. Novel therapies target specific genetic defects, paving the way for personalized, biomarker-driven clinical trials.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Molecular targeted agents are transforming solid tumor treatment.
- Non-small-cell lung cancer (NSCLC) treatment is evolving with targeted therapies for specific genetic defects.
- High-throughput technologies are refining lung cancer classification, revealing diverse molecular subtypes.
Purpose of the Study:
- To discuss how novel technologies and models in lung cancer research can advance biomarker-driven clinical trials.
- To explore the integration of genomic and proteomic data for a comprehensive molecular tumor map.
- To highlight the potential of matching genetic defects and protein interactions with targeted inhibitors.
Main Methods:
- Utilizing high-throughput technologies to analyze genetic abnormalities in lung cancer.
- Combining genomic and proteomic data interrogation.
- Isolating and characterizing cancer stem-like cells for preclinical models.
- Developing patient-derived tumor models in animals.
Main Results:
- The Cancer Genome Atlas Network identified multiple molecular entities within squamous cell lung cancer.
- Genomic and proteomic data integration offers a detailed molecular map of tumors.
- Novel approaches enable matching genetic defects and protein interactions with targeted inhibitors.
- Patient-derived tumor models can recapitulate disease in laboratory settings.
Conclusions:
- Advancements in molecular profiling and preclinical models are crucial for developing effective lung cancer therapies.
- The complexity of lung cancer molecular subtypes necessitates personalized, biomarker-driven treatment strategies.
- Novel technologies and models hold promise for a new era of targeted clinical trials in lung cancer.
